ANNEXON, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.7 USD | +2.40% |
|
+3.07% | +3.52% |
| Apr. 01 | JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating | MT |
| Mar. 27 | Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 10M | Capitalization | 428M |
|---|---|---|---|---|---|
| Net income 2024 * | -151M | Net income 2025 * | -185M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 42.8 x |
| P/E ratio 2024 * |
-3.08
x | P/E ratio 2025 * |
-2.86
x | Employees | 71 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Annexon, Inc.
More recommendations
More press releases
| 1 day | +2.40% | ||
| 1 week | +3.07% | ||
| Current month | -34.45% | ||
| 1 month | -31.69% | ||
| 3 months | +4.44% | ||
| 6 months | +127.05% | ||
| Current year | +3.52% |
1 week
4.26
4.85
1 month
4.268.26
Current year
3.868.40
1 year
1.578.40
3 years
1.5724.85
5 years
1.5738.01
10 years
1.5738.01
| Managers | Title | Age | Since |
|---|---|---|---|
Douglas Love
CEO | Chief Executive Officer | 56 | 14-11-30 |
Jennifer Lew
DFI | Director of Finance/CFO | 51 | 19-05-31 |
Jamie Dananberg
CTO | Chief Tech/Sci/R&D Officer | 66 | 23-07-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Wiggans
CHM | Chairman | 72 | 17-01-31 |
Muneer Satter
BRD | Director/Board Member | 63 | 14-11-30 |
William Carson
BRD | Director/Board Member | 65 | 21-02-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.7 | +2.40% | 1,430,749 |
| 24-04-25 | 4.59 | +3.15% | 1,899,183 |
| 24-04-24 | 4.45 | +0.23% | 3,606,173 |
| 24-04-23 | 4.44 | -2.31% | 855,678 |
| 24-04-22 | 4.545 | -0.33% | 1,157,650 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.7
USD
Average target price
15.17
USD
Spread / Average Target
+222.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.52% | 428M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- ANNX Stock
